#1254865
Microgenics #0039

Toxicology Reagent DRI® Benzodiazepine (BZO) CLIA Non-Waived For Clinical Chemistry Analyzers

Name: Toxicology Reagent
Brand: DRI®

REAGENT, IMMUNOASSAY DRI BENZODIAZEPINE 100ML D/S

Toxicology Reagent DRI® Benzodiazepine (BZO) CLIA Non-Waived For Clinical Chemistry Analyzers

Compare

Product Specifications

McKesson #

1254865

Manufacturer #

0039

Brand

DRI®

Manufacturer

Microgenics

Country of Origin

Unknown

Application

Toxicology Reagent

CLIA Classification

CLIA Non-Waived

CLIA Classified

CLIA Non-Waived

Container Type

Bottle

For Use With

For Clinical Chemistry Analyzers

Form

Ready-to-Use Liquid

Product Dating

McKesson Acceptable Dating: we will ship >= 90 days

Sample Type

Urine Sample

Specialty

Toxicology

Storage Requirements

Requires Refrigeration

Test Category

Drugs of Abuse

Test Method

Homogeneous Enzyme Immunoassay (HEIA)

Test Name

Benzodiazepine (BZO)

Test Type

Single Drug

UNSPSC Code

41116007

Volume

100 mL

Features

The DRI® Benzodiazepine Assay is a homogeneous enzyme immunoassay intended for the qualitative and/or semi-quantitative determination of the presence of benzodiazepines and their metabolites in human urine at a cutoff concentration of 200 ng/mL
The assay is designed for use with a number of clinical chemistry analyzers
The DRI Benzodiazepine Assay is intended for use on automated clinical analyzers capable of maintaining a constant temperature, pipetting, mixing reagents, measuring enzymatic rates at 340 nm and timing the reaction accurately can be used to perform this immunoassay